» This Story:Read +| Comments

Case History

Discussion Policy
Comments that include profanity or personal attacks or other inappropriate comments or material will be removed from the site. Additionally, entries that are unsigned or contain "signatures" by someone other than the actual author will be removed. Finally, we will take steps to block users who violate any of our posting standards, terms of use or privacy policies or any other policies governing this site. Please review the full rules governing commentaries and discussions. You are fully responsible for the content that you post.
Friday, February 8, 2008; Page A06

Case History

Merck's settlement of more than $650 million ends a seven-year legal marathon.

This Story

Dec. 2000: A federal complaint is filed under seal accusing Merck of improper sales practices for its arthritis drug Vioxx and cholesterol drug Zocor after Merck employee H. Dean Steinke sounds the alarm.

Jan. 2003: Steinke's lawyers approach state attorneys general to gauge their interest in the case.

July 2004: A new lead prosecutor is assigned to the case and pronounces the allegations too complicated and the case too difficult to prove.

April 2005: Nevada files its case against Merck after Deputy Attorney General Tim Terry takes an interest.

May 2006: Merck's motion to dismiss the case is denied, and a Nevada federal judge rules that Merck should have reported marketing discounts to the government.

Yesterday: Merck agrees to pay a settlement of more than $650 million. Steinke will receive about $68 million as the whistleblower.

SOURCE: Drugfraudsettlement.com

» This Story:Read +| Comments
© 2008 The Washington Post Company